AAP
BIVV

Ardsley Advisory Partners’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Ardsley Advisory Partners’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,000
Closed -$399K – 186
2017
Q3 		$399K Buy
+7,000
New +$410K 0.05% 101

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Ardsley Advisory Partners's BIVV Position: Q4 2017 in Review

Ardsley Advisory Partners sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 7,000 shares — an estimated $399K sold.

Ardsley Advisory Partners first reported a position in BIVV in Q3 2017 and held it in 1 quarter. The position peaked at $399K in Q3 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Ardsley Advisory Partners reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Ardsley Advisory Partners sold 7,000 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $399K.
  • Ardsley Advisory Partners first reported a position in Bioverativ Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Ardsley Advisory Partners's Bioverativ Inc. Common Stock position peaked at $399K in Q3 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Ardsley Advisory Partners's 13F filing for Q4 2017, filed 14 Feb 2018.